Journal article
Modelling Outcomes of Complex Treatment Strategies Following a Clinical Guideline for Treatment Decisions in Patients with Rheumatoid Arthritis
A Tran-Duy, A Boonen, W Kievit, PLCM van Riel, MAFJ van de Laar, JL Severens
Pharmacoeconomics | ADIS INT LTD | Published : 2014
Abstract
Background: Management of rheumatoid arthritis (RA) is characterised by a sequence of disease-modifying antirheumatic drugs (DMARDs) and biological response modifiers (BRMs). In most of the Western countries, the drug sequences are determined based on disease activity and treatment history of the patients. A model for realistic patient outcomes should reflect the treatment pathways relevant for patients with specific characteristics.Objective: This study aimed at developing a model that could simulate long-term patient outcomes and cost effectiveness of treatment strategies with and without inclusion of BRMs following a clinical guideline for treatment decisions.Methods: Discrete event simul..
View full abstractGrants
Funding Acknowledgements
ATD, WK and PLCMvR declared no conflicts of interest. AB received research grants from Merck, AbbVie and Amgen, and honorarium from Pfizer and VCB. MAFJvdL received honorarium from Abbott, AbbVie, Bristol-Myers Squibb, MSD and Pfizer, fees for participation in review activities from Abbott, AbbVie, Bristol-Myers Squibb, Pfizer and UCB, and payment for lectures from Bristol-Myers Squibb. JLS received a research grant from Pfizer for conducting this study.